Activated Platelets in Carotid Artery Thrombosis in Mice Can Be
                    Selectively Targeted with a Radiolabeled Single-Chain Antibody by Heidt, Timo et al.
Activated Platelets in Carotid Artery Thrombosis in Mice
Can Be Selectively Targeted with a Radiolabeled
Single-Chain Antibody
Timo Heidt
1*
., Friederike Deininger
2., Karlheinz Peter
3.,J u ¨rgen Goldschmidt
4, Annette Pethe
5,
Christoph E. Hagemeyer
3, Irene Neudorfer
1, Andreas Zirlik
1, Wolfgang A. Weber
2, Christoph Bode
1,
Philipp T. Meyer
2, Martin Behe
2., Constantin von zur Mu ¨hlen
1.
1Department of Cardiology and Angiology, University of Freiburg, Freiburg, Germany, 2Department of Nuclear Medicine, University of Freiburg, Freiburg, Germany,
3Baker IDI Heart and Diabetes Institute, Melbourne, Australia, 4Leibniz-Institute for Neurobiology, Magdeburg, Germany, 5Department of Nuclear Medicine, University of
Magdeburg, Magdeburg, Germany
Abstract
Background: Activated platelets can be found on the surface of inflamed, rupture-prone and ruptured plaques as well as in
intravascular thrombosis. They are key players in thrombosis and atherosclerosis. In this study we describe the construction
of a radiolabeled single-chain antibody targeting the LIBS-epitope of activated platelets to selectively depict platelet
activation and wall-adherent non-occlusive thrombosis in a mouse model with nuclear imaging using in vitro and ex vivo
autoradiography as well as small animal SPECT-CT for in vivo analysis.
Methodology/Principal Findings: LIBS as well as an unspecific control single-chain antibody were labeled with
111Indium
(
111In) via bifunctional DTPA (=
111In-LIBS/
111In-control). Autoradiography after incubation with
111In-LIBS on activated
platelets in vitro (mean 3866628 DLU/mm
2, 40106630 DLU/mm
2 and 45206293 DLU/mm
2) produced a significantly higher
ligand uptake compared to
111In-control (2101676 DLU/mm
2, 1181696 DLU/mm
2 and 18666246 DLU/mm
2) indicating a
specific binding to activated platelets; P,0.05. Applying these findings to an ex vivo mouse model of carotid artery
thrombosis revealed a significant increase in ligand uptake after injection of
111In-LIBS in the presence of small thrombi
compared to the non-injured side, as confirmed by histology (49630610650 DLU/mm
2 vs. 1739067470 DLU/mm
2; P,0.05).
These findings could also be reproduced in vivo. SPECT-CT analysis of the injured carotid artery with
111In-LIBS resulted in a
significant increase of the target-to-background ratio compared to
111In-control (1.9960.36 vs. 1.160.24; P,0.01).
Conclusions/Significance: Nuclear imaging with
111In-LIBS allows the detection of platelet activation in vitro and ex vivo
with high sensitivity. Using SPECT-CT, wall-adherent activated platelets in carotid arteries could be depicted in vivo. These
results encourage further studies elucidating the role of activated platelets in plaque pathology and atherosclerosis and
might be of interest for further developments towards clinical application.
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Introduction
Molecular imaging of cells or cellular epitopes is a rapidly
evolving field, which allows non-invasive detection of vascular
pathologies [1,2]. Targeting of surface epitopes in atherosclerosis
has been described in various animal models, allowing detection of
early atherosclerosis or thrombus formation in arterial vessels
[3,4,5]. The detection of intravascular thrombosis is still clinically
challenging and mostly relies on indirect imaging modalities.
Computed tomography angiogram only allows detection of rather
large thrombus formation by indicating an altered contrast flow
surrounding the thrombosis. Small vessel thrombosis in pulmonary
embolism can be detected by scintigraphy, showing a discrepancy
between ventilation and perfusion in the suspected area. However,
direct targeting of the intravascular thrombosis with molecular
imaging would strongly enhance the sensitivity, allowing direct
depiction of even smallest intravascular aggregates and specific
detection of the underlying pathology. An interesting and clinically
relevant target are activated platelets, since they play a key role in
atherosclerosis and atherothrombosis [6]. Activated platelets can
be found on the surface of inflamed non-ruptured plaques [7,8],
and participate in thrombus formation after plaque rupture [6]
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18446leading to myocardial infarction or stroke. Therefore, early and
non-invasive detection of platelets in this context would be of
clinical interest before total thrombotic occlusion of vessels occurs.
Imaging of activated platelets on the surface of arterial thrombosis
has been previously described by our group using molecular
magnetic resonance imaging (MRI) [8,9,10]. As target we
addressed ligand-induced binding sites (LIBS), an epitope that is
exposed by an activation-specific epitope of the platelet glycopro-
tein IIb/IIIa-receptor at the site of thrombus formation. In
contrast, circulating or resting platelets with an inactive glycopro-
tein IIb/IIIa-receptor, for example in the spleen, do not reveal
these binding sites. Targeting these binding sites with a single-
chain antibody that was conjugated to microparticles of iron oxide
(MPIO), which typically cause a signal void in T2*-weighted MRI,
therefore allowed the selective detection of activated platelets in
wall-adherent, non-occlusive thrombosis in carotid arteries of mice
in vivo [8]. However, since iron oxide-based contrast agents cause
a negative contrast, evaluation of the obtained signal is often
disturbed by motion artifacts [11] and small platelet aggregates
that are of interest in the context of plaque inflammation could be
missed due to lack of sensitivity. Therefore, a different imaging
strategy providing improved sensitivity will be needed, especially
with the interest of imaging coronary plaque inflammation or
rupture in the future. Radiotracers provide an excellent sensitivity,
allowing detection down to picomolar concentration [12,13].
Furthermore, in radiotracer imaging motion artifacts such as the
beating heart do not impact sensitivity as severely as in MRI.
Here we describe the construction of a radiotracer specifically
targeting the LIBS-epitope of activated platelets in a mouse model
of carotid artery injury, which imitates the surface of an inflamed
or ruptured plaque. The LIBS-single chain antibody was
conjugated to
111Indium, and binding to activated platelets tested
in vitro by autoradiography. In further steps, this approach was
transferred to a living system, allowing the detection of thrombosis
ex vivo by autoradiography and in vivo by SPECT-CT. The carotid
arteries were identified by CT-angiography, and the images were
fused with the
111In-LIBS SPECT-examination. This approach
allowed the accurate and highly sensitive detection of activated
platelets, which is not only of interest for further application in
smaller vessels such as the coronary arteries, but also for a future
transfer into a human approach.
Methods
Ethics Statement
Care and use of laboratory animals in this study followed the
national guidelines and was approved by the institutional animal
care and ethics committees of the University of Freiburg,
Germany (permit No. 35/9185.81/G-09/47).
LIBS antibody
We used a single-chain antibody that selectively binds to Ligand
Induced Binding Sites (LIBS) at the active conformation of the
glycoprotein IIb/IIIa receptor and induces strong adherence to
activated platelets in the presence of fibrinogen. Antibody
construction as well as binding characteristics have been described
elsewhere [14,15]. As control served a similar single-chain
antibody, however with a scrambled binding domain, that inhibits
specific target binding.
Coupling of DTPA and labeling with
111In
All chemicals were purchased from Sigma-Aldrich (Dreieich,
Germany) if not otherwise indicated.
111InCl3 was obtained from
Covidien (Neustadt/Donau, Germany).
The coupling and the labeling were performed in a similar way
as described by Ehrenreich et al. [16]. Briefly, the LIBS (max.
200 mg/mL; 200 mg) and the control-scFv (7800 mg/mL; 200 mg)
were rebuffered from PBS to an alkine 0.1 M NaHCO3 solution
with a 10 kDa Amicon Ultra 4 cut-off filter (Millipore Corpora-
tion, Molsheim, France). Prior to this, the filter was incubated at
4uC with 1 mg/mL bovine serum albumin (BSA) solution
overnight to saturate free protein binding sites.
Afterwards 5 mg DTPA (p-SCN-Bn-DTPA, Macrocyclics,
Dallas, TX, USA) was dissolved in the NaHCO3 buffer and
pipetted onto the filter vial. After incubation for one hour at room
temperature the filter vial was filled up with 4 mL NaHCO3 buffer
and centrifuged once. The incubation step was repeated once.
The DTPA conjugates were rebuffered to 0.1 M NH4-acetate
buffer (pH 5.4) and three times centrifuged with 4 mL to a final
volume of 1 mL. Finally the concentration of DTPA-scAb was
determined using Bio-Rad Protein Assay (Bio-Rad Laboratories
GmbH, Mu ¨nchen, Germany) and the extinction was measured on
a Spectrometer (SpectraMAX plus, Molecular Devices, Sunny-
vale, CA, USA) at 595 nm.
20 MBq
111InCl3 in 30 mL 0.1 M HCl were added to 40 mgo f
scFvs in a volume of 600–700 mL ammonia acetate buffer (0,1 M;
pH 5,4). For 30 min the sample was incubated at room temper-
ature. Free
111In was separated by filtrating it on an Amicon cut-off
filter by centrifugation with 4 mL NH4-acetate buffer. The
radiochemical purity of the
111In-labeled scAb was evaluated by
running an isocratic HPLC (Ramona Star, raytest GmbH,
Straubenhardt, Germany) on a SEC 125-5 Bio-Silect column
(Bio-Rad) with PBS as eluent. The
111In-labeled LIBS (
111In-LIBS)
and control scFv (
111In-control) were used for the experiments.
Functional testing of conjugated antibody with flow
cytometry
Persistence of LIBS or control single-chain antibody function
after conjugation to DTPA was tested using flow cytometric
analysis. Platelet rich plasma was prepared from human whole
blood as described elsewhere [16]. Non-activated platelets and
platelets activated by adenosine diphosphate (ADP, mo ¨Labora-
tory, Langenfeld, Germany) were examined. After incubation with
conjugated LIBS or control single-chain antibody, platelets were
exposed to a secondary antibody (Penta HIS Alexa Fluor 488,
Qiagen, Hilden Germany) which selectively binds the histidine-tag
of the single-chain antibody constructs, and flow cytometry was
performed gating 10 000 platelets using a FACSCalibur flow
cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). For
signal evaluation we used the program CellQuest 3.3 (CellQuest
Inc.; Tampa, FL, USA).
Autoradiography
Autoradiography was conducted using a highly sensitive
Phosphor Imaging System (Cyclone Plus, PerkinElmer, Waltham,
MA, USA). Results were measured in digital light units per mm
2
(DLU/mm
2). DLU is an arbitrary linear unit that describes the
intensity of photon emissions released during the scan. Exposure
of specimens to the film was conducted in a lead-shielded
surrounding to exclude scattered radiation at 220uC. For signal
evaluation we set a region of interest (ROI) in the middle of each
spot and calculated the mean ligand uptake in DLU/mm
2.
In Vitro analysis of LIBS functional binding to activated
platelets
For in vitro studies of
111In-LIBS function, cell culture wells were
coated with activated or non-activated human platelets. Platelet
Nuclear Imaging of Activated Platelets
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sepharose CL-2B and eluted in phosphate buffered saline (PBS).
Platelet concentration was determined with a Neubauers counting
chamber. Wells (1,9 cm
2) were pretreated with fibrinogen and
blocked with 1% BSA. Then wells were loaded with 200 mlo f
platelet rich solution (80610
5 platelets/well).
111In-labeled LIBS
or labeled control single-chain antibody, respectively, were
incubated on wells, washed three times with PBS at 4uC and
submitted to autoradiographic phosphor imaging with different
antibody doses as measured by radioactivity in kilocounts per
minute (kcpm: 160, 320 and 640 kcpm). Results were evaluated by
defining a ROI in the center of the ligand uptake and measuring
the corresponding DLU/mm
2.
Carotid artery thrombosis model: induction of a wall
adherent, non-occlusive thrombosis
For ex vivo and in vivo experiments we used the well-established
carotid artery thrombosis model in mice [5,17,18]. Sample size
was chosen according to our previous experience with the mouse
carotid artery thrombosis model [15,19]. Ten to 11 week old male
C57BL/6 mice (Charles River, Germany) weighing 2262 g were
anesthetized by s.c.-injection with ketamine (200 mg/kg body
weight) and xylazine (12.5 mg/kg body weight) and were then
placed under a dissecting microscope. A segment of the right
carotid artery was exposed through a superficial incision of the
skin and blunt dissection of the fascia over the vessel. To obtain a
semi-occlusive platelet-rich thrombosis a filter paper (363 mm,
GB003, Schleicher & Schuell) saturated with ferric chloride (6.5%
solution, Sigma, Germany) was placed under the vessel for 3 min.
The wound was then closed with a suture of the skin. We
conducted an incubation of 45 min to allow appositional growth of
the intravascular thrombosis, according to previous experience [5]
prior to our scans. After image acquisition animals were terminally
anesthetized using ketamine and xyalazine, flushed with saline via
the left ventricle, and the injured carotid artery as well as the non-
injured contralateral carotid artery were removed.
Ex Vivo experimental protocol
Mice were assigned to either the LIBS or the control group. Due
to the restricted half-life of radiotracers this was done in blocks of
about 5 animals each. Wall-adherent thrombosis was induced
applying 6.5% ferric chloride for 3 min as described above and the
operation site was closed with a suture. After 45 min, a venous
catheter was placed in the tail vein (Portex, Smiths Medical
International, USA) and 100 ml of radiotracers (
111In-LIBS:
0.9860.36 MBq, about 10 mg LIBS antibody or
111In-control:
0.8661 MBq, about 10 mg control antibody, respectively) were
slowly injected intravenously. Mice were sacrificed 30 min after
injection and flushed with physiological saline solution via the left
ventricle to clear the vessels from blood. The injured as well as the
contralateral carotid were then carefully resected to avoid
contamination with tracer remnants, washed and wrapped in
plastic foil. At 220uC vessels were placed on the phosphor
imaging plate for about 24 hours. The contralateral side served as
reference for the assessment of the background noise in each
vessel.
In vivo experimental and SPECT-CT protocol
For in vivo imaging we again used the carotid artery thrombosis
model described above. Compared to ex vivo models, in vivo
studies require higher doses of antibody (about 10 fold) to ensure
sufficient radioactivity for non-invasive detection of the area of
interest. This may hinder a direct comparison between studies, but
doses within each study were consistent. Radiolabeled
111In-LIBS
(16.7566.28 MBq) or
111In-control (13.9666.97 MBq) was in-
jected via the tail vein catheter. Animals were placed in an animal
bed and anesthesia was continuously transferred from ketamine to
1% isoflurane in O2.
Scans were performed using a dedicated high resolution small
animal SPECT-CT imager (NanoSPECT-CT imager, Bioscan).
First, a CT-angiogram of the neck region was conducted for
detailed anatomical information of the carotid arteries. The field
of view covered 20.4 mm. Images were acquired over 90 sec with
180 projections (exposure time per projection: 500 msec; peak
tube voltage: 45 kV; tube current: 177 mA) Using a syringe pump
(Harvard Apparatus, Holliston, USA) Imeron 350 iodinated CT
contrast (Byk Gulden, Konstanz, Germany) was continuously
delivered at a rate of 200 ml/min throughout image acquisition as
described elsewhere. [20,21]. CT images were reconstructed with
a resolution of 200 mm.
SPECT analysis of the same area was assessed using a four head
system with multi-pinhole collimators (9 pinholes per head,
1.4 mm). Each of 24 projections to cover 360 degree was
measured for 600 sec with a total scan time of 60 min. Acquisition
time in one case was doubled due to 50% reduction of the activity
used (1200 sec and 120 min, respectively). Photopeaks for
111Indium were set to 171 keV and 245 keV65%. SPECT
images were reconstructed using the software InvivoScope
(Bioscan).
As CT and SPECT images are generated sequentially we
realigned images using a three dimensional external fiducial
containing 1 MBq of 99m-technetium (
99mTc) in a small plastic
tubing (Portex, Smith Medical, Ashford, Kent, UK) detectable
with CT and firmly fixed to the neck region of the mice. After
image reconstruction this three dimensional landmark was used
for exact realignment of CT and SPECT images. Photopeaks for
99mTc were set to 140 keV65%. Images were reconstructed to a
voxel size of 300 mm. Finally carotids were harvested for
histological workup.
Evaluation of SPECT-CT images and quantification of
signals
Image rendering was conducted using the DICOM viewer
Osirix 3.7.1 (Pixmeo, Geneve, Switzerland). Evaluation of
SPECT-CT images was done with InvivoScope software (Bioscan).
The ligand uptake, displayed in counts per minute (min), was
converted to kilobecquerel (KBq) by defining a quantification
factor using a fix amount of
111Indium in a water phantom as a
reference. For each specimen we correlated the images of the
injured vessel with histology (see below) to locate the intravascular
thrombosis. We then calculated a ratio of the mean ligand uptake
per volume at this area divided by a mean ligand uptake per
volume of three surrounding VOIs (Volume of interest) to
represent the uptake in the surgical bed. Selection of VOIs based
on the CT image only to avoid bias. Single VOIs in the area of the
vessel injury had a mean size of 0.6860.08 mm
3. The VOIs of the
surrounding were chosen with a mean size of 3.6360.3 mm
3 to
represent a large area to reduce the noise.
Tissue harvesting and histology
As described previously, animals were terminally anesthetized
with ketamine and xylazine after the scans. The injured as well as
the contralateral carotid arteries were then removed, embedded in
OCT TissueTec (Sakura Finetec, Netherlands) and frozen for
histology. For our ex vivo experiments the vessels were soaked with
OCT and wrapped into plastic for autoradiographic evaluation
prior to the final embedding. Frozen tissue was cut in transversal
Nuclear Imaging of Activated Platelets
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the thrombosis we identified the bifurcation of the carotid artery as
a landmark that could be easily detected by histology and on the
rendered CT image. Setting the carotid bifurcation as a
benchmark we received a measure for the best placement of the
VOI. For the detection and quantification of wall-adherent
thrombosis, mouse platelets were detected by immunohistological
staining using a rat anti-mouse glycoprotein IIb (CD41) polyclonal
antibody (Clone MWReg30, GeneTex, USA). The primary
antibody was detected using a rabbit anti-rat biotinylated
secondary antibody (Vectastain ABC-AP Kit, Vector, Germany)
and VectorRed (Vector, Germany). For each animal, representa-
tive sections were chosen and the degree of thrombosis was
quantified in percent of the total vessel lumen using Axiovision
Software (Carl Zeiss, Germany).
Statistical methods
All data represent the mean value 6 SD. The impact of the
results as well as the difference in tracer uptake between the
arterial thrombosis and the surrounding were tested via an
unpaired, two sided t-test. Test results were considered significant
when p,0.05.
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agreed to the
manuscript as written.
Results
Labeling and In vitro binding of
111In-labeled LIBS to
activated platelets
The
111In-labeled single-chain antibody fragments showed an
111In-labeling efficacy of 68.868.7%. After purification the
radiochemical purity was more than 90%. In vitro experiments
with DTPA coupled LIBS antibody using flow cytometry
confirmed the persistence of selective binding to activated platelets
after conjugation to DTPA (Figure 1A) and isotope labeling
(Figure 1B). As shown in Figure 1A, incubation of activated
platelets with labeled LIBS results in a relevant shift which is not
seen after incubation on rested platelets or incubation with labeled
control antibody. Afterwards, three groups with ADP-activated
platelets were incubated with either
111In-LIBS or
111In-control at
increasing doses of radiolabeled antibody (160, 320 and 640
kilocounts per minute (kcpm)). By measuring the ligand uptake
with autoradiographic imaging, we demonstrated the selective
binding of
111In-labeled antibodies to activated platelets compared
to non-specific binding qualities of
111In-control (Figure 1B). At all
antibody doses, incubation with
111In-LIBS produced a signifi-
cantly higher ligand uptake (mean 3866628 DLU/mm
2,
40106630 DLU/mm
2 and 45206293 DLU/mm
2) compared to
111In-control (2101676 DLU/mm
2, 1181696 DLU/mm
2 and
18666246 DLU/mm
2, P,0.05, n=6).
Figure 1. In vitro analysis of specific
111In-LIBS binding to activated platelets. (A) Flow cytometric analysis of platelets, non-activated (-ADP)
and activated (+ADP), after incubation with DTPA-labeled LIBS or control as indicated. After incubation with DTPA-labeled LIBS, activated platelets
showed a clear shift indicating specific target binding (above, Q). This was not seen after incubation on non-activated platelets or application of the
control antibody (below, Q) (B) Autoradiographic imaging of incubated
111In-LIBS on activated platelets compared to
111In-control. Ligand uptake is
depicted in digital light units/mm
2 (DLU, y-axis) after incubation with increasing antibody doses, as measured by radioactivity (in kilocounts per
minute (kcpm); in parenthesis the protein mass used): 160 kcpm (29 ng), 320 kcpm (58 ng) and 640 kcpm (116 ng), respectively (x-axis). A significant
increase in ligand uptake is registered after incubation with
111In-LIBS (left column) compared to
111In-Control (right column) at every activity level
(n=6; P,0.05). Given are mean values 6 one standard deviation.
doi:10.1371/journal.pone.0018446.g001
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in carotid artery thrombosis
A wall-adherent non-occlusive arterial thrombosis was induced
in mice and labeled antibodies were injected. This was well
tolerated by all animals. After incubation mice were sacrificed, the
carotid arteries harvested and analyzed (Figures 2A and 2B). To
ensure a relevant but non-occlusive thrombosis, we only selected
specimens with a thrombosis .10% and ,80% for further data
evaluation (mean 40621%). The degree of thrombosis did not
relevantly differ between groups (
111In-LIBS: n=5; mean
42626%,
111In-control: n=5; mean 38618%).
Next to the evaluation of the injured carotid artery, evaluation
of the contralateral non-injured carotid artery served as a negative
control and predominantly as reference of remnant radioactivity in
the non-injured vessel (Figure 2C).
Comparing the ligand uptake of the injured with the
contralateral reference vessel (n=5 vs. 5) after incubation with
111In-LIBS revealed a significant increase in ligand uptake at the
side of the intravascular thrombosis (Figure 3A; 49630610650
DLU/mm
2 compared to 1739067470 DLU/mm
2, P,0.05). In
contrast, incubation with
111In-control (n=5) caused no significant
elevation of the ligand uptake, but revealed only a subtle signal
Figure 2. Ex vivo autoradiography of carotid artery thrombosis. Ex vivo autoradiography of carotid artery specimens (left column) and
appendent transversal histology sections of carotid arteries immunohistochemically stained for CD41 (right column). Autoradiography of the injured
carotid artery, after treatment with ferric chloride, reveals a strong ligand uptake after incubation with
111In-LIBS (A). Corresponding histology proves
the presence of a non-occlusive wall-adherent thrombosis. After incubation with
111In-control, the radioligand uptake appears visually decreased (B).
Autoradiography of the carotid artery on the contralateral non-injured side allowed the assessment of background radiation in the absence of an
intravascular thrombosis (C).
doi:10.1371/journal.pone.0018446.g002
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mm
2 compared to 13736385 DLU/mm
2; P=n.s.). As the area of
interest in the carotid arteries is very small, the initial incubation
time on the autoradiographic film was extended to ensure a
sufficient signal uptake knowing the risk of image overexposure.
This technical issue did however not affect results and was
considered not relevant in this ex vivo proof-of-concept. Therefore
incubation time was not changed to preserve consistency.
SPECT-CT imaging of carotid artery thrombosis in mice
After induction of a thrombus in the right carotid artery, we
injected either
111In-LIBS or
111In-control via a tail vein catheter.
Thereafter, mice were placed in the small animal SPECT-CT
scanner and carotid arteries were localized using contrast
enhanced computed tomography of the neck region. Continuous
infusion of Imeron 350 throughout the scan was well tolerated by
the animals (Figure 4A). SPECT imaging of the same region was
performed without moving the animal (Figure 4B). Prelude whole
body biodistribution imaging directly after i.v.-injection showed
rapid blood pool clearance of the antibodies with predominantly
renal but also low hepatobiliary elimination of tracers (data not
shown). Based on this data, SPECT imaging was started 30 min
after tracer injection, directly following the CT-angiography.
Exact overlay of images was supported using small external
radioactive, CT sensitive three dimensional marker. Figure 4C
illustrates the overlay of SPECT and CT data, figures 4D and E
represent three dimensionally rendered images of the CT-
angiogram and the SPECT-CT. As seen in figure 4C the SPECT
ligand uptake visually projects to the site of the vessel injury with a
peak uptake on the injured vessel. Uptake was found not only in
the injured vessel, but also in the adjacent surrounding (surgical
bed) which however was considerably lower. To overcome the
interference of ligand uptake at the surgical site with the uptake of
the injured vessel, we adopted the surgical bed as background and
analyzed a target-to-background ratio to show the increase of
ligand uptake after incubation with
111In-LIBS compared to
111In-
control in the area of the vessel injury (as shown in Figure 5A).
Incubation with
111In-LIBS resulted in a significant increase of this
target-to-background ratio (mean ratio 1.9960.36; n=4) com-
pared to incubation with
111In-control (ratio 1.160.24; n=4;
Figure 5B); p,0.01. Ligand uptake of the contralateral non-
injured carotid was equivalent to unspecific uptake, for example in
the muscle.
Discussion
Imaging of atherosclerosis and its structural changes in the
vessel wall is an emerging field of investigational interest as it
provides an approach to early detection of cardiovascular disease.
Platelets take part in early as well as in late steps of atherosclerosis
and are key players in the development of atherothrombosis [8]. In
this study, we describe imaging of activated platelets with a
radiopharmaceutical consisting of a single-chain antibody target-
ing ligand-induced binding sites of the activated fibrinogen
receptor glycoprotein IIb/IIIa (aIIbb3, CD41/CD61) labeled with
111Indium.
111Indium was chosen for several reasons for the radiolabeling
of LIBS. The conjugation with the chelator DTPA is very easy and
offers a one pot labeling. The labeling with
18F (as a PET nuclide)
of proteins is very limited due to a complex chemistry combined
with a short half life of the nuclide (110 min). Additionally,
111In
has good physical properties with a half life of 2.8 days and can be
used as a SPECT radionuclide which shows a better resolution in
small animals (,1 mm) compared to PET (e.g.
68Ga.3 mm).
Despite the better sensitivity of PET we chose
111In for an initial
proof-of-principle due to the higher resolution in small animals
and the much easier chemistry combined with a longer half-life.
Previous studies investigating paramagnetic labeled LIBS
antibody with magnetic resonance imaging (MRI) have already
elucidated the unique binding qualities of this antibody to
selectively target activated platelets with high specificity [5,9,15].
Using an in vitro setup of activated human platelets we confirmed
this specific binding to activated platelets with nuclear autoradio-
graphic imaging by showing a significant increase in ligand uptake
that occurred exclusively after incubation with
111In-LIBS.
Therefore,
111In-LIBS antibody can be used to selectively depict
activated platelets and seems to be suitable for the detection of
intravascular thrombosis with nuclear imaging techniques.
To evaluate the potential of
111In-LIBS to detect activated
platelets on the surface of intravascular arterial thrombosis in an in
vivo situation, we transferred this contrast agent approach to a
mouse model of wall-adherent non-occlusive thrombosis. Others
have previously described the imaging of activated platelets with
Figure 3. Evaluation of ex vivo autoradiographic results. Autoradiographic results after incubation of the injured and non-injured carotid
artery with
111In-LIBS or
111In-Control. Compared to the contralateral non-injured side, indicated as ‘‘Background‘‘, incubation with
111In-LIBS results in
a significant increase in the absolute autoradiographic ligand uptake (DLU/mm
3) of the injured carotid artery (A; n=5; P,0.05). Changes in uptake
were not significant after incubation with
111In-control (B; n=5, p=n.s.). Ex vivo results indicate a specificity of
111In-LIBS for targeting activated
platelets.
doi:10.1371/journal.pone.0018446.g003
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[22,23]. However, imaging activated platelets under the high shear
stress of arterial flow remains challenging. Ex vivo autoradiography
allowed the direct assessment of
111In-LIBS target binding after
exposure to arterial flow conditions and natural elimination from
the blood pool with high sensitivity [24]. To guarantee the
presence of a relevant thrombosis and to ensure blood flow over its
surface for the delivery of sufficient bioavailability of radiotracer,
Figure 4. In vivo SPECT-CT imaging of carotid artery thrombosis. In vivo SPECT-CT single (A, B) and fused (C) images after injury of the right
carotid artery (right side) and incubation with
111In-labeled LIBS. CT angiogram of the neck region enhanced with iodinated contrast (Imeron 350)
provides vessel contrast for anatomical detail of the carotid arteries (A, R=right carotid vessel, L=left carotid vessel); three-dimensional
reconstruction of the CT-angiogram (D). SPECT imaging of the same neck region after incubation with
111In-LIBS depicts a co-localized peak of
111In-
uptake (kBq/voxel). Three-dimensional overlay of CT data (D) with SPECT signal allows the correlation of the peak uptake to the area of the injured
carotid artery (E) Movies of the three-dimensionally rendered images are provided as supporting information (Movie S1, Movie S2).
doi:10.1371/journal.pone.0018446.g004
Figure 5. Evaluation of in vivo SPECT-CT results. (A) SPECT images were evaluated with reference to the anatomical information provided by CT
and based on the information gathered from histological sections about the location of the intravascular thrombosis. To compare the intravascular
ligand uptake with the ligand uptake in the surgical bed, we defined 4 VOIs: A small VOI to best represent the target area of the thrombosis (mean
0.68 60.08 mm
3; black box) surrounded by 3 reference VOIs (mean 3.6360.3 mm
3) with fixed location to assess ligand uptake in the surgical bed
(cubes with an edge length of 1–2 mm; white boxes). From these VOIs we calculated a target to region ratio (i.e., mean uptake per volume in the
black box divided by the mean uptake per volume of all white boxes). Comparing the ratio after injection of
111In-LIBS and
111In-control reveals a
significant increase in ligand uptake after incubation with
111In-LIBS (B, P,0,01).
doi:10.1371/journal.pone.0018446.g005
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as confirmed by histology (10–80% of the total vessel occlusion).
After injection of the contrast agent and incubation, both carotid
vessels were resected and analyzed with autoradiography. The
assessment of the contralateral non-injured side served for the
measurement of the remnant background radiation. Non-specific
uptake was expected due to the extremely high sensitivity of this
autoradiographic approach and was minimized by perfusion of
vessels with physiological saline solution. Uptake of the injured
carotid artery was, hence, evaluated in the context of the present
background radiation. The significant increase in ligand uptake
after injection of
111In-LIBS compared to
111In-control proved a
sufficient target binding of
111In-LIBS even under arterial flow
conditions to allow a highly sensitive detection of activated
platelets and intravascular thrombosis in the direct assessment of
carotid specimens ex vivo.
However, as in vitro and ex vivo studies are artificial constructs
that are not likely to fully cover the complexity of an in vivo
environment, we used a dedicated small-animal SPECT-CT
scanner to evaluate the capability of
111In-LIBS to also detect
platelet activation and intravascular thrombosis in vivo.
Nuclear imaging techniques such as SPECT provide the
possibility of functional analysis of in vivo processes, allowing the
detection of even small amounts of bound ligands down to
picomolar concentration [25]. However the techniques suffer from
unclear anatomical localization of the radioactive uptake. This can
be overcome by using hybrid imaging, combining SPECT’s
functional analysis using
111In-LIBS for delivery of information
about the localization of activated platelets inside the vessel with
CT angiography for detailed anatomical information allowing the
accurate identification of the carotid arteries.
Since radiotracer-methods provide an excellent sensitivity
exceeding the properties of other molecular imaging contrast agents
and techniques [12], the combination of these two techniques is a
promising approach for characterization of atherosclerosis. Other
studies have described successful application of SPECT-CT for the
characterization of atherosclerosis. Using a radioligand against the
oxidized low-density lipoprotein receptor, molecular imaging of
atherosclerotic plaques was possible in a murine model, and
imaging signal was associated with markers of rupture-prone
atherosclerotic plaques [26]. Also evaluation of atherosclerosis by
in vivo SPECT-CT has been described, targeting annexin and
matrix-metalloproteinase inhibitors [27,28]. Also the activity of
matrix-metalloproteinases in atherosclerotic lesions of New Zealand
rabbitswasdetectable bySPECTand allowedmonitoring ofdietary
modification and statin treatment [29]. However, to our knowledge,
imaging of platelets has not yet been described in the context of
atherothrombotic diseases. Sensitive and specific imaging would be
of interest, since platelets can be found on the surface of inflamed,
rupture-prone plaques and are early indicators of plaque rupture
[6,7,8].These properties exceedthe advantage obtained by imaging
of other thrombus components, such as described with fibrin or D-
dimer antibodies, which have been recently used to image
pulmonary emboli by SPECT [30].
By showing a significant increase in the target to background
ratio after injection of
111In-LIBS by SPECT that could be well
correlated with the presence of a relevant arterial thrombosis, we
were able to detect platelet activation in advanced atherothrom-
botic disease. Having proven the concept of this approach, next
steps will now use the high sensitivity of nuclear imaging
techniques to further investigate the surface of inflamed endothe-
lium and rupture prone plaques to identify and elucidate the role
of platelets in inflammatory processes and the development of
atherosclerosis.
Furthermore, direct non-invasive targeting of intravascular
thrombosis would be a unique and novel approach to detect
arterial, but also venous thrombosis at much higher sensitivity
compared to the known imaging techniques such as CT
angiography or ventilation-perfusion scintigraphy. The prerequi-
sites for a bench to bedside transfer of LIBS-scFv are excellent.
LIBS-scFv was initially designed for application on human
platelets acting as activation-specific antagonist of their gpIIb/
IIIa-receptor. ScFvs are a small functional form of an antibody,
only consisting of the variable regions of the antibody’s heavy and
light chain fused together via a short linker molecule, and can be
produced in bacteria at low costs [31,32]. The specificity of its
target binding is unique, and target affinity is comparable to
clinically used gpIIb/IIIa antagonists. The small size of the LIBS-
scFv (about 32 kDa) allows for good accessibility and penetration
of the thrombus [32] as well as rapid blood pool clearance via the
kidney of non-bound labeled protein. Fortunately, cross-reactivity
with mouse platelets allows the assessment of the LIBS-antibody as
a probe for molecular imaging in mouse models. Nuclear imaging
techniques have been used for years to detect molecular receptors
in oncology [33] and encounter broad clinical acceptance.
Therefore, nuclear imaging of activated platelets would be a first
step towards clinical application. A transfer from bench to bedside
would be certainly challenging but worthwhile with regards to the
therapeutic benefits. While the risk of immunogenicity is extremely
low [31], selective targeting of activated platelets provides
pathophysiologic information which allows for individual risk
stratification and will help to guide therapeutic strategies.
Favorable non-radioactive molecular imaging techniques such as
MRI with MPIOs for the detection of activated platelets have also
been evaluated by our group [5]. These techniques are certainly
promising, however have not yet reached the level of clinical
applicability due to potential toxicity of the contrast-giving
molecules.
A possible limitation of the animal model applied in our study
for further functional evaluation of
111Indium-LIBS is the need of
the carotid artery to be directly exposed for the reliable and
reproducible induction of wall-adherent thrombosis. Thereby, a
wound area reaching from the skin surface towards the artery is
created, allowing non-specific radiotracer deposition in edematous
tissue but also specific binding to activated platelets involved into
hemostasis. This is the reason for the high signal background in
the wound area seen in both animal groups, after injection of
111In-control but also with
111In-LIBS. However, the uptake signal
caused by specific binding of
111In-LIBS at the carotid artery
thrombosis is still sufficient to obtain a highly significant signal.
The reason for applying this model in our study in spite of these
disadvantages is its reproducibility [5], which is an important
prerequisite in a proof-of-concept-study. We are currently
evaluating alternative animal models to overcome this limitation.
Conclusions
We describe the construction of a radioligand based on a single-
chain antibody specifically targeting activated platelets in an in vivo
mouse model of wall-adherent non-occlusive thrombosis in the
carotid artery, which imitates the surface of an inflamed or
ruptured plaque. In all approaches applying in vitro, ex vivo and in
vivo techniques, the
111In-LIBS radiotracer enabled the sensitive
detection of wall-adherent activated platelets, such as found in
atherothrombosis or plaque inflammation. SPECT-CT allowed
the identification of the carotid artery as well as the accurate and
highly sensitive detection of wall-adherent activated platelets.
These results encourage further studies elucidating the role of
activated platelets in plaque pathology and atherosclerosis and are
Nuclear Imaging of Activated Platelets
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since the timely detection of platelet activation on the vessel wall
could allow for the individual risk assessment in cardiovascular
disease.
Supporting Information
Movie S1 Three-dimensional rendering of the CT
angiogram. Ex vivo three-dimensional rendering of the CT
angiogram provides detailed anatomical information of the carotid
arteries’ location.
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Movie S2 Three-dimensional rendering of the SPECT-
CT. In vivo tree-dimensional rendering of the SPECT-CT after
carotid injury and incubation with
111In-LIBS. Ligand uptake
projects to the area of the carotid injury. Additionally, some ligand
uptake can also be found in the orbita of the contralateral side,
which is due to contrast agent deposition in the Harder’s gland.
(MOV)
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